Atypical small acinar proliferation: Difference between revisions
No edit summary |
m Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +) |
||
Line 17: | Line 17: | ||
{{SCC}} | {{SCC}} | ||
==Overview== | ==Overview== | ||
Line 40: | Line 40: | ||
{{Urogenital neoplasia}} | {{Urogenital neoplasia}} | ||
[[Category:Pathology]] | [[Category:Pathology]] |
Revision as of 22:36, 8 August 2012
Template:DiseaseDisorder infobox
Steven C. Campbell, M.D., Ph.D.
Overview
In urologic pathology, atypical small acinar proliferation, abbreviated ASAP, is a collection of small prostatic glands, on prostate biopsy, whose significance is uncertain and cannot be determined to be benign or malignant.
ASAP, generally, is not considered a pre-malignancy, or a carcinoma in situ; it is an expression of diagnostic uncertainty,[1] and analogous to the diagnosis of ASCUS (atypical squamous cells of undetermined significance) on the Pap test.
Association with adenocarcinoma
On a subsequent biopsy, given the diagnosis of ASAP, the chance of finding prostate adenocarcinoma is approximately 40%; this is higher than if there is high-grade prostatic intraepithelial neoplasia (HGPIN).[2]
Management
ASAP is considered an indication for re-biopsy.[3]
See also
References
- ↑ Flury SC, Galgano MT, Mills SE, Smolkin ME, Theodorescu D (2007). "Atypical small acinar proliferation: biopsy artefact or distinct pathological entity". BJU International. 99 (4): 780–5. Unknown parameter
|month=
ignored (help) - ↑ Leite KR, Camara-Lopes LH, Cury J, Dall'oglio MF, Sañudo A, Srougi M (2008). "Prostate cancer detection at rebiopsy after an initial benign diagnosis: results using sextant extended prostate biopsy". Clinics. 63 (3): 339–42. PMID 18568243. Unknown parameter
|month=
ignored (help) - ↑ Bostwick DG, Meiers I (2006). "Atypical small acinar proliferation in the prostate: clinical significance in 2006". Arch. Pathol. Lab. Med. 130 (7): 952–7. PMID 16831049. Unknown parameter
|month=
ignored (help)